Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vedolizumab Clear all
Completed No phase listed Observational Results available

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

NCT04852666
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 28, 2026, 8:26 PM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Active, not recruiting No phase listed Observational

Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease

NCT07123350
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
Interventions
Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

NCT03657160
View directory record Official record
Conditions
Hematopoietic Stem Cells
Interventions
Vedolizumab Placebo, Vedolizumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Early Phase 1 Interventional

Synergistic Effect of Vedolizumab and Pentoxifylline

NCT02953275
View directory record Official record
Conditions
Crohn Disease
Interventions
vedolizumab, Pentoxifylline, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

NCT04779307
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 4 Interventional Results available

Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762
View directory record Official record
Conditions
Crohn Disease
Interventions
Vedolizumab, Adalimumab, Methotrexate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Results available

Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

NCT02788175
View directory record Official record
Conditions
HIV
Interventions
Entyvio (Vedolizumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 28, 2026, 8:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

NCT04407247
View directory record Official record
Conditions
Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma
Interventions
Infliximab, Vedolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 4 Interventional Results available

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

NCT03798691
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

NCT02611830
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 28, 2026, 8:26 PM EDT
Recruiting Phase 2 Interventional

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

NCT06841705
View directory record Official record
Conditions
Immune Checkpoint Inhibitor-Related Colitis
Interventions
Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim
Drug · Other
Lead sponsor
Shilpa Grover, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Terminated No phase listed Observational

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

NCT03802214
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Not applicable Interventional

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases

NCT02862132
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Shaare Zedek Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Hartford, Connecticut • Morristown, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 28, 2026, 8:26 PM EDT
Recruiting No phase listed Observational

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

NCT06750731
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
Interventions
Tappt
Device
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
New Orleans, Louisiana • Chevy Chase, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 1 Interventional Results available

Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

NCT02728895
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Sep 28, 2026, 8:26 PM EDT
Terminated Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

NCT02723006
View directory record Official record
Conditions
Melanoma
Interventions
TAK-580, TAK-202, vedolizumab, nivolumab, ipilimumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease

NCT00790933
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 28, 2026, 8:26 PM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 28, 2026, 8:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

NCT00783718
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
102
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 28, 2026, 8:26 PM EDT
Completed No phase listed Observational

Characterization of CD Responders to Vedolizumab

NCT04909359
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 28, 2026, 8:26 PM EDT